<!DOCTYPE html>

<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/ -->
<!--[if lt IE 7]> <html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js lt-ie9 lt-ie8" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js lt-ie9" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en"> <!--<![endif]-->
<head>
	<meta charset="utf-8" />

	<!-- Set the viewport width to device width for mobile -->
	<meta name="viewport" content="width=device-width" />

	<title>PracticeUpdate : News Item</title>

	<!-- Included CSS Files -->
<!-- FontDeck
<link rel="stylesheet" href="http://f.fontdeck.com/s/css/l4MsFun30OJhB9DTDGcb8JQSAOQ/practicenetwork-foundation/22889.css" type="text/css" /> 
-->

	<link rel="stylesheet" href="assets/css/app.css">
	<link rel="stylesheet" href="assets/css/font-awesome.css">
	<link rel="stylesheet" href="assets/css/fc-webicons.css">
	<link rel="stylesheet" href="assets/css/foundation-icons-general.css">

	<script src="assets/js/foundation/modernizr.foundation.js"></script>

	<!-- sharethis code -->
<script type="text/javascript">var switchTo5x=true;</script>
<script type="text/javascript" src="http://w.sharethis.com/button/buttons.js"></script>
<script type="text/javascript">stLight.options({publisher: "f3b4e78b-9a7f-4bd8-900f-c0b05425275f", doNotHash: true, doNotCopy: true, hashAddressBar: false});</script>

<!-- End sharethis -->

<!-- hootsuite -->

<!-- end hootsuite -->

	<!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script>
    <![endif]-->

</head>
	<body id="page" class="update off-canvas slide-nav news-item logged-out">
  <div class="widget ad">
    <div id="leaderboard" class="Breast ad-container">
      <div class="ad-title"><span class="ad-title-text">advertisement</span></div><!--/.ad-title-->
      <div id="leaderboardcontent" class="ad-content">
			</div><!--.ad-content-->
		</div><!--/#leaderboard.ad-container-->
  </div><!--/.widget.ad-->
	<div class="page-header">
	</div><!--/.page-header-->
	<div class="page-content">
	<section role="main">

<div class="single-item-container">
	<article class="type-blog single-item">
	<div class="item-header-container">
		<header class="item-header">
			<div class="flag-container"><span class="flag featured"><i class="icon-bolt"></i> featured</span></div>
			<div class="meta pub-meta">
				<span class="item-type">News</span>
				<span class="item-pub-date"><time datetime="12-12-05">December 05, 2012</span>
			</div>
			<hgroup class="item-title-container">
				<h1 class="item-title">Second-Line FOLFIRI/Aflibercept Ups Survival in Metastatic Colorectal Cancer</h1>
				<p class="item-citation">{{source.citation}}</p>
			</hgroup>
<!-- http://support.addthis.com/customer/portal/articles/381263-addthis-client-api#rendering-preferred-services -->

<!-- AddThis Button BEGIN -->
<div class="addthis_toolbox addthis_default_style ">
<a class="addthis_button_preferred_1"></a>
<a class="addthis_button_preferred_2"></a>
<a class="addthis_button_preferred_3"></a>
<a class="addthis_button_preferred_4"></a>
<a class="addthis_button_compact"></a>
<a class="addthis_counter addthis_bubble_style"></a>
</div>
<script type="text/javascript">var addthis_config = {"data_track_addressbar":true};</script>
<script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-50f715661b6cff2d"></script>
<!-- AddThis Button END -->

			<div class="sharethis-actions">
				<span class='st_facebook' displayText='Facebook'></span>
				<span class='st_twitter' displayText='Tweet'></span>
				<span class='st_googleplus' displayText='Google +'></span>
				<span class='st_linkedin' displayText='LinkedIn'></span>
				<span class='st_email' displayText='Email'></span>			
			</div><!--/.sharethis-actions-->

			<div class="hootsuite-actions">
<!-- hootsuite hootlet 
http://hootsuite.com/social-share
-->
<a href="[URL]" title="[MESSAGE]" class="_hs_socialshare">Share</a>

<script>
var _hs = {
	size: 1
};
(function() {
	var h = document.createElement('script'); h.type = 'text/javascript'; h.async = true;
	h.src = ('https:' == document.location.protocol ? 'https://' : 'http://') + 'd2l6uygi1pgnys.cloudfront.net/hootlet.js';
	var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(h, s);
})();
</script>
<!-- End hootsuite -->
			</div><!--/.hootsuite-actions-->
				<!-- <p class="source"> --><!-- {{source}} --><!-- J Clin Oncol. 2012 Aug 27;[Epub Ahead of Print], HSL Jim, KM Phillips, S Chait</p>--><!--/.source-->
				<!-- <h2 class="item-subtitle">Article Subtitle - Optional</h2> -->
			<!-- <div class="item-description">
				<p>In this commentary, Dr. Scher discusses his research on a novel androgen receptor signaling inhibitor, MDV3100, which was shown to improve survival in a post-chemotherapy population of men with progressive castration-resistant prostate cancer (CRPC).</p>
			</div> --><!--/.description-->
				<!-- <div class="meta taxonomy-meta">
				<p>Find more items about these topics:</p>
				<ul class="tag-list">
					<li>
						<i class="icon-tags"></i><a class="label label-tag" href="#">Prostate</a>
					</li> -->
				<!-- </ul> --><!--/.tag-list-->
			<!-- </div> --><!--/.taxonomy-meta-->
		</header>
	</div><!--/.item-header-container-->
	<div class="item-content-container">	
		<div class="item-content">
			<div class="item-content-section">
				<section class="commentary">
					<div class="commentary-container">
							<p>Metastatic colorectal cancer is generally treated initially with a regimen of fluorouracil and leucovorin plus either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI). Patients cross over to the alternate regimen for second-line therapy. The antiangiogenic agent bevacizumab has been shown to increase survival in patients with metastatic colorectal cancer in the first-line setting when added to FOLFIRI and in the second-line setting when added to FOLFOX, but no biologic agent has been shown to improve survival in the second-line setting when added to FOLFIRI.</p><p>Aflibercept is a recombinant fusion protein that targets three factors that contribute to tumor angiogenesis: vascular endothelial growth factor A (VEGFA), VEGFB, and placental growth factor (PlGF). In a multinational phase III study sponsored by Sanofi, Van Cutsem et al added aflibercept to FOLFIRI as second-line therapy for metastatic colorectal cancer previously treated with oxaliplatin. Prior bevacizumab was allowed, but not prior irinotecan.</p><p>Between 2007 and 2010, a total of 1226 patients were randomized to receive aflibercept 4 mg/kg (n = 612) or placebo (n = 614) on day 1 every 2 weeks, followed by the FOLFIRI regimen (irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2 bolus and then 2400 mg/m2 by continuous infusion). Crossover to aflibercept after progression on placebo was not permitted.</p><p>At the February 2011 cutoff date for analysis of overall survival (OS), the primary endpoint, median follow-up was 22.28 months. The patients receiving aflibercept/FOLFIRI had a median survival of 13.50 months compared with 12.06 months for the placebo/FOLFIRI control patients (hazard ratio [HR], 0.817; P = .0032). At 2 years, survival rates were 28.0% and 18.7%, respectively. The treatment effect favoring aflibercept held in analyses of prespecified subgroups based on prior bevacizumab use and various patient characteristics at baseline.</p><p>Progression-free survival (PFS) increased from 4.7 months for controls to 6.9 months with use of aflibercept (HR, 0.758; P &lt; .0001). Subgroup analyses showed a consistent trend in PFS in favor of aflibercept. The response rate in patients with measurable disease was significantly higher with aflibercept vs placebo (19.8% vs 11.1%; P &lt; .001).</p><p>Grade 3 and 4 adverse events were more common with aflibercept than placebo (83.5% vs 62.5%, respectively). Toxicities related to anti-VEGF treatment were consistent with those reported in previous studies. Interestingly, some common adverse events related to treatment with FOLFIRI were more frequent in the aflibercept arm. These included grade 3 and 4 diarrhea, asthenia, stomatitis, infections, and palmar&#8211;plantar erythrodysesthesia, as well as grade 3 and 4 neutropenia, thrombocytopenia, and neutropenic complications.</p><p>The addition of aflibercept to FOLFIRI led to a relative reduction in the risk of death of 18.3%, compared with placebo/FOLFIRI. The early and continued divergence of the survival curves further supports the clinical value of the aflibercept results. Survival rates for aflibercept vs placebo were 38.5% vs 30.9% at 18 months, 28.0% vs 18.7% at 24 months, and 22.3% vs 12.0% at 30 months.</p><p>The authors concluded that aflibercept plus FOLFIRI may be a new therapeutic option for the treatment of metastatic colorectal cancer patients whose disease has progressed while on or after completion of an oxaliplatin-based regimen.</p>
					</div><!--/.commentary-container-->
				</section><!-- /.commentary-->
			</div><!-- ./item-content-section -->
			<div class="item-content-section">
				<section class="video">
<div class="flex-video">
  <!-- <iframe width="420" height="315" src="http://www.youtube.com/embed/9otNWTHOJi8" frameborder="0" allowfullscreen></iframe> -->
  <iframe width="560" height="315" src="http://www.youtube.com/embed/b6Tmu7LLKEs" frameborder="0" allowfullscreen></iframe>
</div>
</section><!--/.video-->
</div><!--/.item-content-section-->
				<hr />
		</div><!--/.item-content-->
	</div><!--/.item-content-container-->
<footer class="copyright item-footer">
<img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"/>
<p>Copyright &copy; 2012 International Medical News Group</p>
</footer>
</div><!--/.item-container-->
				<div id="aux" class="recommended">
				<div id="video-prompt-ad" class="ad">
					<img data-src="holder.js/300x250/text:MOA Video image">
					<a class="button" data-reveal-id="modal-video-ad" style="display:block;">Click to play video</a>
				</div><!--/#video-prompt-ad-->	
				<div class="recent">
				</div><!--/.recent-->
				<div class="ad">
					<img src="http://placehold.it/300x250" align="ad" title="ad" />
				</div>
				</div><!--/.recommended-->

	</section><!--/[role="main"]-->
	<section id="sidebar" role="complementary">
		<div class="dashboard">
			<div class="panel cta register">
				<p><!-- Meet Our Experts --> Become a member to customize this page.<p>
				<a class="button" href="#action-register">Register for free</a>
			</div><!--/.panel.cta.register-->
			<div class="component user-console">
			</div><!--/.component.user-console-->

			<div class="component user-topic">
			</div><!--/.component.user-topic-->
			<div class="component topic-spotlight">
			</div><!--/.component.topic-spotlight-->
			<div class="panel">
				<img src="http://placehold.it/200x200" /><p><!-- Meet Our Experts --> Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.<p>
			</div>
		</div><!--/.sidebar-->
	</section><!--/.[role="complimentary"]-->
</div><!--/.page-content-->
	<footer class="page-footer">
	</footer><!-- /.page-footer -->

	<!-- Included JS Files (Uncompressed) -->
  <script src="assets/js/foundation/jquery.js"></script>
  
	<script src="assets/js/foundation/jquery.foundation.accordion.js"></script>
	<script src="assets/js/foundation/jquery.foundation.alerts.js"></script>	
	<script src="assets/js/foundation/jquery.foundation.buttons.js"></script>
	<script src="assets/js/foundation/jquery.foundation.forms.js"></script>
	<script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js"></script>
	<script src="assets/js/foundation/jquery.foundation.navigation.js"></script>
	<script src="assets/js/foundation/jquery.foundation.orbit.js"></script>
	<script src="assets/js/foundation/jquery.foundation.reveal.js"></script>
	<script src="assets/js/foundation/jquery.foundation.tabs.js"></script>
	<script src="assets/js/foundation/jquery.foundation.tooltips.js"></script>
	<script src="assets/js/foundation/jquery.placeholder.js"></script>


	<script src="assets/js/foundation/app.js"></script>
	<script src="assets/js/foundation/jquery.offcanvas.js"></script>

	
	<script src="assets/js/mustache.js"></script>

	<!-- Placeholder - for replacing placeholder images -->
	<script src="assets/js/holder.js"></script>

	<!-- Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
		$.get('assets/mustache/feed-item.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.stream-container').html(html);
		});

	});

	<!-- Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
		$.get('assets/mustache/recent.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.recent').html(html);
		});

	});

	<!-- Mustache - homepage user-console template -->
	$.getJSON('content/json/user-console.json', function(data) {
		$.get('assets/mustache/user-console.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.user-console').html(html);
		});
	});

		<!-- Mustache - homepage user-topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
		$.get('assets/mustache/user-topic.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.user-topic').html(html);
		});
	});

	<!-- Mustache - homepage topic-spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
		$.get('assets/mustache/topic-spotlight.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.topic-spotlight').html(html);
		});
	});	
	</script>

	<!-- Page Modal -->
	<div id="modal-video-ad" class="reveal-modal">
<div class="modal-header">
<h3>
    Histology Matters: Personalized Therapy for Patients with NSCLC
</h3>
<p class="cme-description">An interactive CME activity provided by the Johns Hopkins University School of Medicine</p>
  </div><!--/.modal-header-->
  <div class="modal-body">
<div class="flex-video">
  <!-- <iframe width="420" height="315" src="http://www.youtube.com/embed/9otNWTHOJi8" frameborder="0" allowfullscreen></iframe> -->
  <iframe width="560" height="315" src="http://www.youtube.com/embed/b6Tmu7LLKEs" frameborder="0" allowfullscreen></iframe>
</div>
  </div><!--/.modal-body-->
  <div class="modal-footer">

    <p>FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angiodema have been reported in associations with FASLODEX. See full Important Safety Information at the conclusion of the video.</p>
    <a target="_blank" href="http://www.jhasim1.com/index.aspx?case_id=120" class="button">start learning</a>
    <span>*Estrogen receptor |
    Full PI</span> 

                <img data-source="holder.js/200x200/text:AZ branding image" />
  </div><!--/.modal-footer-->
<a class="close-reveal-modal">×</a> 
	</div><!-- /.modal-video-ad-->

</body>
</html>